Researchers at the University of California San Diego have isolated a marine bacterium compound called rutamycin B that kills the brain-eating amoeba Naegleria fowleri within four hours. The finding targets primary amoebic meningoencephalitis, an infection carrying a fatality rate exceeding 97 percent.
Speed and Potency of Rutamycin B Versus Standard Treatment
Primary amoebic meningoencephalitis, commonly known as PAM, progresses through the central nervous system with devastating speed, often giving patients only a few days to mount a response. The disease destroys brain tissue rapidly and leaves almost no survivors.
The newly isolated marine-derived compound demonstrates significant potency at low concentrations against multiple clinical strains of the parasite. While amphotericin B, the current gold-standard treatment, takes roughly 16 hours to reach full strength, rutamycin B achieves full potency within just four hours.
Current treatments for PAM often act too slowly or carry heavy toxicity.
Laboratory testing revealed that the compound proved 200 to 300 times more lethal to the parasite than to human cells. Mechanistically, it operates by shutting down an enzyme that the amoeba relies upon to generate energy. Current treatments for the condition are frequently too slow or carry heavy toxicity to be effective against such a rapid progression.
Rutamycin B Reduces Toxicity When Combined with Standard Treatments
Beyond its standalone speed, rutamycin B shows strong potential for reducing treatment toxicity. When researchers combined the marine compound with the existing standard treatment, they achieved identical results while utilizing as little as 3% to 10% of the original dose of rutamycin B. Findings could lay the foundation for future treatments that fundamentally improve survival rates when paired with existing therapies.
By identifying a compound that is both faster and more selective, we are moving closer to a treatment that can stop the infection before it causes irreversible damage, which could fundamentally change the prognosis for people who contract this parasite.
The research team believes the structural characteristics of the molecule make it a promising candidate for further pharmacological refinement. Because the target infection resides in the central nervous system, upcoming studies will evaluate whether the compound can successfully cross the blood-brain barrier and test its efficacy in live disease models. Further research remains necessary before this approach transitions into clinical practice.
The findings were detailed in a study published in Marine Drugs titled Antiamoebic Activity of Rutamycin B and Inhibition of Naegleria fowleri F1FO ATP Synthase Activity, led by Debnath, Fenical, and Hayley Fong, PhD, who completed this project as part of her doctoral research at UC San Diego. National Institutes of Health grants R21EY034294 and R21AI171538 provided partial funding for the research. An international application (PCT/US26/18919) was filed on March 12, 2026, related to this work.
Readers evaluating these findings should consult qualified medical or research professionals regarding health-agency guidance, clinical contexts, and regulatory status, rather than drawing independent medical conclusions from preclinical evidence.